Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Abdominal pain (AP)-associated functional gastrointestinal disorders (FGIDs), particularly
Irritable Bowel Syndrome (IBS) and Functional Dyspepsia (FD), are common in pediatrics, and
no safe and effective treatment is available. Although probiotics have shown promising
results in adults, few studies have been published in children. The Bifidobacterium Infantis,
Bifidobacterium Breve and Bifidobacterium Longum are the most important beneficial bacteria
in children and represent 95% of the total bacterial population in the intestine of breastfed
infant.
Objectives: 1) To evaluate the effect of oral administration of a mixture of Bifidobacteria
on the improvement of frequency and intensity of AP in children with FD and IBS. 2) To
evaluate the effect of oral administration of a mixture of Bifidobacteria on quality of life
in children with FD and IBS.